Intellia Therapeutics, Inc. SEC filings NTLA
Intellia Therapeutics, Inc. has 721 filings in SEC EDGAR's recent list, going back to Sep 3, 2015. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| CT ORDER | Filing | Sep 1, 2020 | — |
| EFFECT | Filing | Sep 12, 2019 | — |
| CORRESP | Letter to the SEC | Sep 10, 2019 | — |
| CORRESP | Letter to the SEC | Aug 30, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 29, 2019 | — |
| EFFECT | Filing | Jun 6, 2019 | — |
| CORRESP | Letter to the SEC | Jun 4, 2019 | — |
| CT ORDER | Filing | May 9, 2019 | — |
| CT ORDER | Filing | Mar 11, 2019 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2019 | — |
| POSASR | Filing | Feb 27, 2019 | — |
| EFFECT | Filing | Jun 16, 2017 | — |
| CORRESP | Letter to the SEC | Jun 15, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2017 | — |
| CT ORDER | Filing | Feb 7, 2017 | — |
| CT ORDER | Filing | Dec 22, 2016 | — |
| CT ORDER | Filing | May 6, 2016 | — |
| CERTNAS | Auto-generated paper document | May 5, 2016 | — |
| EFFECT | Filing | May 5, 2016 | — |
| 8-A12B | Filing | May 5, 2016 | — |
| CORRESP | Letter to the SEC | May 3, 2016 | — |
| CORRESP | Letter to the SEC | May 3, 2016 | — |
| CORRESP | Letter to the SEC | Apr 27, 2016 | — |
| CORRESP | Letter to the SEC | Apr 27, 2016 | — |
| CORRESP | Letter to the SEC | Apr 22, 2016 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2016 | — |
| CORRESP | Letter to the SEC | Apr 11, 2016 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2016 | — |
| DRS/A | Filing | Mar 17, 2016 | — |
| UPLOAD | Letter from the SEC | Jan 11, 2016 | — |
| DRS/A | Filing | Dec 22, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 29, 2015 | — |
| DRS/A | Filing | Oct 14, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2015 | — |
| DRS | Filing | Sep 4, 2015 | — |
| D | Filing | Sep 3, 2015 | — |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NTLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1652130
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.